Japan Quasi Drugs vs Cosmetics and Where Your Product Lands

Most regulatory systems sort products into two buckets: cosmetic or drug. Japan has three. Sitting between an ordinary cosmetic and a full pharmaceutical is the quasi-drug category, and it exists precisely because a lot of everyday personal care products make claims stronger than "moisturizes" but not quite at the level of treating a diagnosed medical condition.

What quasi-drug means under the PMD Act

Japan's Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, generally referred to as the PMD Act, is the framework governing pharmaceuticals, medical devices, cosmetics, and this in-between quasi-drug category. Quasi-drugs are products that have a specific, government-recognized active function beyond ordinary cosmetic effects, but don't require the full clinical evidence and prescribing framework of a pharmaceutical.

The category exists because there's a real, common set of consumer products, think medicated shampoos, whitening serums with active ingredients, and certain deodorants, that make functional claims stronger than "cleanses" or "moisturizes" without being medicine in the way a prescription treatment is. Japan built a regulatory lane specifically for that middle ground rather than forcing everything stronger than basic cosmetics through full drug approval.

The claims that tend to trigger it

If you're formulating a product intended for the Japanese market, or considering it, certain functional claims are strong signals you're heading into quasi-drug territory rather than staying in the cosmetic lane:

• Whitening or brightening claims tied to specific active ingredients intended to affect pigmentation, rather than general "brightens the look of skin" cosmetic language
• Anti-acne claims where the product is positioned as treating or preventing acne through an active ingredient, not just cleansing skin prone to it
• Sunscreen and UV protection claims, similar to how sunscreen sits outside ordinary cosmetics regulation in several other markets
• Antiperspirant claims where the product is stopping perspiration through an active mechanism, distinct from a deodorant simply masking odor
• Medicated claims generally, anywhere the product name or marketing implies a therapeutic or preventive function tied to a recognized active ingredient

This pattern will look familiar if you've dealt with other markets. Sunscreen, anti-acne, anti-dandruff, and antiperspirant products commonly get treated as something other than an ordinary cosmetic in multiple regulatory systems, because the functional claim crosses from cosmetic into a category requiring more substantiation. Japan's quasi-drug tier is its own specific version of that pattern, with its own approval and ingredient requirements layered under the PMD Act.

Why the classification changes your whole process

Quasi-drug status in Japan typically brings a more involved approval pathway than standard cosmetic notification, often requiring the product formulation and specific active ingredients to be reviewed against recognized standards before sale. That's a materially different process than a straightforward cosmetic filing, both in terms of timeline and the depth of documentation expected.

Category	General nature	Example products
Cosmetic	General cleansing, beautifying, ordinary care claims	Standard soap, basic moisturizer, shampoo without medicated claims
Quasi-drug	Recognized functional effect beyond ordinary cosmetic claims	Medicated shampoo, whitening serum with active ingredient, certain antiperspirants
Pharmaceutical	Full drug claims, treating or curing diagnosed conditions	Prescription-strength treatments

What to do before you commit to a claim

If Japan is a market you're actively targeting, the practical move is deciding your claims language before you finalize formulation, not after. A product built and labeled around a whitening or medicated claim needs to go in with eyes open about the quasi-drug pathway from the start, rather than discovering partway through that the marketing language you'd planned pushes the product into a different regulatory lane than you budgeted time and cost for.

This kind of cross-market classification question, where the same product might be an ordinary cosmetic in one country and something regulated more heavily in another, is exactly the sort of thing worth mapping out market by market before you commit to a single global label. Cosmetic Comply currently handles Canadian notification filings, with the US, EU, and Australia in development, and part of thinking through a multi-market launch is recognizing early which markets, Japan included, may need a different regulatory conversation entirely.